Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of MoonLake Immunotherapeutics (NASDAQ: MLTX) was $11.17 for the day, down -0.18% from the previous closing price of $11.19. In other words, the price has decreased by -$0.18 from its previous closing price. On the day, 1.61 million shares were traded. MLTX stock price reached its highest trading level at $11.695 during the session, while it also had its lowest trading level at $11.105.
Ratios:
Our analysis of MLTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.50 and its Current Ratio is at 8.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
Goldman Downgraded its Buy to Neutral on October 01, 2025, while the target price for the stock was maintained at $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 08 ’25 when Santos da Silva Jorge sold 130,000 shares for $15.08 per share. The transaction valued at 1,960,400 led to the insider holds 2,948,577 shares of the business.
Santos da Silva Jorge sold 70,000 shares of MLTX for $1,014,300 on Dec 09 ’25. The Chief Executive Officer now owns 2,878,577 shares after completing the transaction at $14.49 per share. On Dec 08 ’25, another insider, Reich Kristian, who serves as the Chief Scientific Officer of the company, sold 130,000 shares for $15.08 each. As a result, the insider received 1,960,400 and left with 72,908 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 791365440 and an Enterprise Value of 409111744.
Stock Price History:
The Beta on a monthly basis for MLTX is 1.20, which has changed by -0.76769775 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, MLTX has reached a high of $62.75, while it has fallen to a 52-week low of $5.95. The 50-Day Moving Average of the stock is -11.77%, while the 200-Day Moving Average is calculated to be -67.75%.
Shares Statistics:
MLTX traded an average of 2.90M shares per day over the past three months and 1221660 shares per day over the past ten days. A total of 63.70M shares are outstanding, with a floating share count of 63.49M. Insiders hold about 10.39% of the company’s shares, while institutions hold 60.07% stake in the company. Shares short for MLTX as of 1765756800 were 4894840 with a Short Ratio of 1.69, compared to 1763078400 on 3856500. Therefore, it implies a Short% of Shares Outstanding of 4894840 and a Short% of Float of 13.73.
Earnings Estimates
. The current rating of MoonLake Immunotherapeutics (MLTX) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.68 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$3.46 and -$3.69 for the fiscal current year, implying an average EPS of -$3.58. EPS for the following year is -$3.58, with 10.0 analysts recommending between -$1.83 and -$4.36.
